Warning Letters

Matters described in FDA warning letters may have been subject to subsequent interaction between FDA and the letter recipient that may have changed the regulatory status of issues discussed in the letter.
To obtain additional available information, contact FDA. Requests to FDA for agency records should be sent to: Food and Drug Administration Division of Freedom of Information (HFI-35), 5630 Fishers Lane, Rockville, MD 20857. Instructions for how to submit an FOI request can be found at How to Make a FOIA Request.

Filter by

Issuing Office

Letter Issue Date

Letters with Response or Closeout

Posted Date

Year

Posted Date	Letter Issue Date	Company Name	Issuing Office	Subject
09/12/2023	08/21/2023	RickinmortyBars	Center for Tobacco Products	Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
09/12/2023	09/01/2023	Vape Society Supply	Center for Tobacco Products	Family Smoking Prevention and Tobacco Control Act/Adulterated/Misbranded
09/12/2023	07/18/2023	Del Valle Import & Export 3, Inc. DBA El Progreso Imports	Division of West Coast Imports	Foreign Supplier Verification Program (FSVP)
09/12/2023	09/05/2023	Safecor Health, LLC	Division of Pharmaceutical Quality Operations I	CGMP/Finished Pharmaceuticals/Adulterated
09/12/2023	09/11/2023	TRP Company, Inc	Center for Drug Evaluation and Research \| CDER	Unapproved New Drugs/Misbranded
09/12/2023	09/11/2023	Natural Ophthalmics, Inc.	Center for Drug Evaluation and Research \| CDER	Unapproved New Drugs/Misbranded
09/12/2023	09/11/2023	CVS Health	Center for Drug Evaluation and Research \| CDER	Unapproved New Drugs/Misbranded
09/12/2023	09/11/2023	Boiron, Inc.	Center for Drug Evaluation and Research \| CDER	Unapproved New Drugs/Misbranded
09/12/2023	09/11/2023	DR Vitamins, LLC dba DR Vitamin Solutions	Center for Drug Evaluation and Research \| CDER	Unapproved New Drugs/Misbranded
09/12/2023	09/11/2023	Similasan AG	Center for Drug Evaluation and Research \| CDER	CGMP/Finished Pharmaceuticals/Adulterated/Unapproved New Drug